Advertisement

Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women

  • J. A. KanisEmail author
  • C. Cooper
  • R. Rizzoli
  • J.-Y. Reginster
  • on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF)
Correction
  • 201 Downloads

Correction to: Osteoporos Int

  https://doi.org/10.1007/s00198-018-4704-5

The original version of this article, published on 15 October 2018, unfortunately, contained a mistake.

Table 1 of the paper above stated that the remaining lifetime risk of hip fracture for a woman from Sweden age 80 years was 49.3%. The correct figure should be 19.3%.

Notes

Compliance with ethical standards

Conflict of interest

JAK reports grants from Amgen, Eli Lilly and Radius Health; non-financial support from Medimaps, and Asahi; and other support from AgNovos. JAK is the architect of FRAX® but has no financial interest. CC reports personal fees from Alliance for Better Bone Health, Amgen, EliLilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. RR has received consulting fees or advisory board fees from Radius Health, Labatec, Danone, Nestlé, CNIEL andSandoz. J-YR has received advisory boardor consulting fees from IBSA-Genévrier, Pierre Fabre, Radius Health, TEVA and Mylan; and lecture fees from Anovos, IBSA-Genévrier, Mylan, CNIEL, Dairy Research Council (DRC) and Theramex; and institutional grant support from IBSA-Genévrier, Mylan, CNIEL and Radius Health.

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  • J. A. Kanis
    • 1
    • 2
    Email author
  • C. Cooper
    • 3
    • 4
  • R. Rizzoli
    • 5
  • J.-Y. Reginster
    • 6
    • 7
  • on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF)
  1. 1.Centre for Metabolic Bone DiseasesUniversity of Sheffield Medical SchoolSheffieldUK
  2. 2.Mary McKillop Health InstituteAustralian Catholic UniversityMelbourneAustralia
  3. 3.MRC Lifecourse Epidemiology UnitUniversity of SouthamptonSouthamptonUK
  4. 4.NIHR Musculoskeletal Biomedical Research UnitUniversity of OxfordOxfordUK
  5. 5.University Hospitals and Faculty of Medicine of GenevaGenevaSwitzerland
  6. 6.Department of Public Health, Epidemiology and Health EconomicsUniversity of LiègeLiègeBelgium
  7. 7.Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of ScienceKing Saud UniversityRiyadhKingdom of Saudi Arabia

Personalised recommendations